A subset of CD4/CD8 double-negative T cells expresses HIV proteins in patients on antiretroviral therapy

Journal of Virology

Volumn 90, Issue 5, 2016, Pages 2165-2179

  DeMaster, Laura K ^a   Liu, Xiaohe ^b   VanBelzen, D Jake ^a   Trinité, Benjamin ^c   Zheng, Lingjie ^a   Agosto, Luis M ^d   Migueles, Stephen A ^e   Connors, Mark ^e   Sambucetti, Lidia ^b   Levy, David N ^c   Pasternak, Alexander O ^f   O'Doherty, Una ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b SRI INTERNATIONAL   (United States)

^c NEW YORK UNIVERSITY   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; GAG PROTEIN; NEF PROTEIN; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN; CD4 ANTIGEN; CD8 ANTIGEN;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FIBER OPTICS; FIBEROPTIC ARRAY SCANNING TECHNOLOGY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERNALIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; BIOSYNTHESIS; CHEMISTRY; FLUORESCENCE IMAGING; HIV INFECTIONS; T LYMPHOCYTE SUBPOPULATION; VIROLOGY;

ANTI-RETROVIRAL AGENTS; ANTIGENS, CD4; ANTIGENS, CD8; FLOW CYTOMETRY; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV INFECTIONS; HUMANS; OPTICAL IMAGING; T-LYMPHOCYTE SUBSETS;

EID: 84961123477     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01913-15     Document Type: Article

References (91)

1. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, Smith K, Lisziewicz J, Lori F, Flexner C, Quinn TC, Chaisson RE, Rosenberg E, Walker B, Gange SJ, Gallant J, Siliciano RF. 1999. Latent infection of CD4+T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 5:512-517. http://dx.doi.org/10.1038/8394.
2. Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H, Hermankova M, Chadwick K, Margolick J, Quinn TC, Kuo YH, Brookmeyer R, Zeiger MA, Barditch-Crovo P, Siliciano RF. 1997. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387:183-188. http://dx.doi.org/10.1038/387183a0.
3. Wong JK, Hezareh M, Günthard HF, Havlir DV, Ignacio CC, Spina CA, Richman DD. 1997. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278:1291-1295. http://dx.doi.org/10.1126/science.278.5341.1291.
4. Ho YC, Shan L, Hosmane NN, Wang J, Laskey SB, Rosenbloom DI, Lai J, Blankson JN, Siliciano JD, Siliciano RF. 2013. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 155:540-551. http://dx.doi.org/10.1016/j.cell.2013.09.020.
5. Cullen BR. 1990. The HIV-1 Tat protein: an RNA sequence-specific processivity factor? Cell 63:655-657. http://dx.doi.org/10.1016/0092-8674(90)90129-3.
6. Sodroski JG, Rosen CA, Haseltine WA. 1984. Trans-acting transcriptional activation of the long terminal repeat of human T lymphotropic viruses in infected cells. Science 225:381-421. http://dx.doi.org/10.1126/science.6330891.
7. Laspia MF, Rice AP, Mathews MB. 1989. HIV-1 Tat protein increases transcriptional initiation and stabilizes elongation. Cell 59:283-292. http://dx.doi.org/10.1016/0092-8674(89)90290-0.
8. Fisher AG, Feinberg MB, Josephs SF, Harper ME, Marselle LM, Reyes G, Gonda MA, Aldovini A, Debouk C, Gallo RC, Wong-Staal F. 1986. The trans-activator gene of HTLV-III is essential for virus replication. Nature 320:367-371. http://dx.doi.org/10.1038/320367a0.
9. Dayton AI, Sodroski JG, Rosen CA, Goh WC, Haseltine WA. 1986. The trans-activator gene of the human T cell lymphotropic virus type III is required for replication. Cell 44:941-947. http://dx.doi.org/10.1016/0092-8674(86)90017-6.
10. Malim MH, Hauber J, Le S-Y, Maizel JV, Cullen BR. 1989. The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA. Nature 338:254-257. http://dx.doi.org/10.1038/338254a0.
11. Karn J, Stoltzfus CM. 2012. Transcriptional and posttranscriptional regulation of HIV-1 gene expression. Cold Spring Harb Perspect Med 2:a006916.
12. Yukl S, Pillai S, Li P, Chang K, Pasutti W, Ahlgren C, Havlir D, Strain M, Gunthard H, Richman D, Rice AP, Daar E, Little S, Wong JK. 2009. Latently-infected CD4+ T cells are enriched for HIV-1 Tat variants with impaired transactivation activity. Virology 387:98-108. http://dx.doi.org/10.1016/j.virol.2009.01.013.
13. Furtado MR, Callaway DS, Phair JP, Kunstman BS, Stanton JL, Macken CA, Perelson AS, Wolinsky SM. 1999. Persistence of HIV-1 transcription in peripheral blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med 340:1614-1622. http://dx.doi.org/10.1056/NEJM199905273402102.
14. Lewin SR, Vesana M, Kostrikis L. 1999. Use of real-time PCR and molecular beacons to detect virus replication in human immunodeficiency virus type 1-infected individuals on prolonged effective antiretroviral therapy. J Virol 73:6099-6103.
15. Patterson BK, McCallister S, Schutz M, Siegel JN, Shults K, Flener Z, Landay A. 2001. Persistence of intracellular HIV-1 mRNA correlates with HIV-1-specific immune responses in infected subjects on stable HAART. AIDS 15:1635-1641. http://dx.doi.org/10.1097/00002030-200109070-00005.
16. Kaiser P, Joos B, Niederost B, Weber R, Gunthard HF, Fischer M. 2007. Productive human immunodeficiency virus type 1 infection in peripheral blood predominantly takes place in CD4/CD8 double-negative T lymphocytes. J Virol 81:9693-9706. http://dx.doi.org/10.1128/JVI.00492-07.
17. Pace MJ, Graf EH, Agosto LM, Mexas AM, Male F, Brady T, Bushman FD, O'Doherty U. 2012. Directly infected resting CD4+ T cells can produce HIV Gag without spreading infection in a model of HIV latency. PLoS Pathog 8:e1002818. http://dx.doi.org/10.1371/journal.ppat.1002818.
18. Graf EH, Pace MJ, Peterson BA, Lynch LJ, Chukwulebe SB, Mexas AM, Shaheen F, Martin JN, Deeks SG, Connors M, Migueles SA, O'Doherty U. 2013. Gag-positive reservoir cells are susceptible to HIV-specific cytotoxic T lymphocyte mediated clearance. PLoS One 8:e71879. http://dx.doi.org/10.1371/journal.pone.0071879.
19. Saleh S, Wightman F, Ramanayake S, Alexander M, Kumar N, Khoury G, Pereira C, Purcell D, Cameron PU, Lewin SR. 2011. Expression and reactivation of HIV in a chemokine induced model of HIV latency in primary resting CD4+ T cells. Retrovirology 8:80. http://dx.doi.org/10.1186/1742-4690-8-80.
20. Dahabieh MS, Ooms M, Simon V, Sadowski I. 2013. A doubly fluorescent HIV-1 reporter shows that the majority of integrated HIV-1 is latent shortly after infection. J Virol 87:4716-4727. http://dx.doi.org/10.1128/JVI.03478-12.
21. Bullen CK, Laird GM, Durand CM, Siliciano JD, Siliciano RF. 2014. New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med 20:425-429. http://dx.doi.org/10.1038/nm.3489.
22. Collman R, Balliet JW, Gregory SA, Friedman H, Kolson DL, Nathanson N, Srinivasan A. 1992. An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1. J Virol 66:7517-7521.
23. Balliet JW, Kolson DL, Eiger G, Kim FM, McGann KA, Srinivasan A, Collman R. 1994. Distinct effects in primary macrophages and lymphocytes of the human immunodeficiency virus type 1 accessory genes vpr, vpu, and nef: mutational analysis of a primary HIV-1 isolate. Virology 200:623-631. http://dx.doi.org/10.1006/viro.1994.1225.
24. Carter CC, Onafuwa-Nuga A, McNamara LA, Riddell J, Bixby D, Savona MR, Collins KL. 2010. HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs. Nat Med 16: 446-451. http://dx.doi.org/10.1038/nm.2109.
25. Humeau LM, Binder GK, Lu X, Slepushkin V, Merling R, Echeagaray P, Pereira M, Slepushkina T, Barnett S, Dropulic LK, Carroll R, Levine BL, June CH, Dropulic B. 2004. Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load. Mol Ther 9:902-913. http://dx.doi.org/10.1016/j.ymthe.2004.03.005.
26. Leyva FJ, Anzinger JJ, McCoy JP, Jr, Kruth HS. 2011. Evaluation of transduction efficiency in macrophage colony-stimulating factor differentiated human macrophages using HIV-1 based lentiviral vectors. BMC Biotechnol 11:13. http://dx.doi.org/10.1186/1472-6750-11-13.
27. Page KA, Landau NR, Littman DR. 1990. Construction and use of a human immunodeficiency virus vector for analysis of virus infectivity. J Virol 64:5270-5276.
28. Arya SK, Guo C, Josephs SF, Wong-Staal F. 1985. Trans-activator gene of human T-lymphotropic virus type III (HTLV-III). Science 229:69-73. http://dx.doi.org/10.1126/science.2990040.
29. Levy DN, Aldrovandi GM, Kutsch O, Shaw GM. 2004. Dynamics of HIV-1 recombination in its natural target cells. Proc Natl Acad Sci U S A 101:4204-4209. http://dx.doi.org/10.1073/pnas.0306764101.
30. Trinité B, Chan CN, Lee CS, Mahajan S, Luo Y, Muesing MA, Folkvord JM, Pham M, Connick E, Levy DN. 2014. Suppression of Foxo1 activity and down-modulation of CD62L (L-selectin) in HIV-1 infected resting CD4 T cells. PLoS One 9:e110719. http://dx.doi.org/10.1371/journal.pone.0110719.
31. Trinité B, Ohlson EC, Voznesensky I, Rana SP, Chan CN, Mahajan S, Alster J, Burke SA, Wodarz D, Levy DN. 2013. An HIV-1 replication pathway utilizing reverse transcription products that fail to integrate. J Virol 87:12701-12720. http://dx.doi.org/10.1128/JVI.01939-13.
32. O'Doherty U, Swiggard WJ, Malim MH. 2000. Human immunodeficiency virus type 1 spinoculation enhances infection through virus bind-ing. J Virol 74:10074-10080. http://dx.doi.org/10.1128/JVI.74.21.10074-10080.2000.
33. Plesa G, Dai J, Baytop C, Riley JL, June CH, O'Doherty U. 2007. Addition of deoxynucleosides enhances human immunodeficiency virus type 1 integration and 2LTR formation in resting CD4+ T cells. J Virol 81:13938-13942. http://dx.doi.org/10.1128/JVI.01745-07.
34. Korin YD, Zack JA. 1999. Nonproductive human immunodeficiency virus type 1 infection in nucleoside-treated G0 lymphocytes. J Virol 73: 6526-6532.
35. Yang H, Yorke E, Hancock G, Clutton G, Sande N, Angus B, Smyth R, Mak J, Dorrell L. 2013. Improved quantification of HIV-1-infected CD4+ T cells using an optimised method of intracellular HIV-1 gag p24 antigen detection. J Immunol Methods 391:174-178. http://dx.doi.org/10.1016/j.jim.2013.03.001.
36. Liszewski MK, Yu JJ, O'Doherty U. 2009. Detecting HIV-1 integration by repetitive-sampling Alu-gag PCR. Methods 47:254-260. http://dx.doi.org/10.1016/j.ymeth.2009.01.002.
37. Boom R, Sol CJ, Salimans MM, Jansen CL, Wertheim-van Dillen PM, van der Noordaa J. 1990. Rapid and simple method for purification of nucleic acids. J Clin Microbiol 28:495-503.
38. Pasternak AO, Adema KW, Bakker M, Jurriaans S, Berkhout B, Cornelissen M, Lukashov VV. 2008. Highly sensitive methods based on seminested real-time reverse transcription-PCR for quantitation of human immunodeficiency virus type 1 unspliced and multiply spliced RNA and proviral DNA. J Clin Microbiol 46:2206-2211. http://dx.doi.org/10.1128/JCM.00055-08.
39. Swiggard WJ, Baytop C, Yu JJ, Dai J, Li C, Schretzenmair R, Theodosopoulos T, O'Doherty U. 2005. Human immunodeficiency virus type 1 can establish latent infection in resting CD4+ T cells in the absence of activating stimuli. J Virol 79:14179-14188. http://dx.doi.org/10.1128/JVI.79.22.14179-14188.2005.
40. Korin YD, Zack JA. 1998. Progression to the G1b phase of the cell cycle is required for completion of human immunodeficiency virus type 1 reverse transcription in T cells. J Virol 72:3161-3168.
41. Baldauf HM, Pan X, Erikson E, Schmidt S, Daddacha W, Burggraf M, Schenkova K, Ambiel I, Wabnitz G, Gramberg T, Panitz S, Flory E, Landau NR, Sertel S, Rutsch F, Lasitschka F, Kim B, Konig R, Fackler OT, Keppler OT. 2012. SAMHD1 restricts HIV-1 infection in resting CD4(+) T cells. Nat Med 18:1682-1687. http://dx.doi.org/10.1038/nm.2964.
42. Lahouassa H, Daddacha W, Hofmann H, Ayinde D, Logue EC, Dragin L, Bloch N, Maudet C, Bertrand M, Gramberg T, Pancino G, Priet S, Canard B, Laguette N, Benkirane M, Transy C, Landau NR, Kim B, Margottin-Goguet F. 2012. SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates. Nat Immunol 13:223-228. http://dx.doi.org/10.1038/ni.2236.
43. Stefanová I, Dorfman JR, Germain RN. 2002. Self-recognition promotes the foreign antigen sensitivity of naive T lymphocytes. Nature 420:429-434. http://dx.doi.org/10.1038/nature01146.
44. Ochsenbauer C, Edmonds TG, Ding H, Keele BF, Decker J, Salazar MG, Salazar-Gonzalez JF, Shattock R, Haynes BF, Shaw GM, Hahn BH, Kappes JC. 2012. Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages. J Virol 86:2715-2728. http://dx.doi.org/10.1128/JVI.06157-11.
45. Das M, Riess JW, Frankel P, Schwartz E, Bennis R, Hsieh HB, Liu X, Ly J C, Zhou L, Nieva JJ, Wakelee HA, Bruce RH. 2012. ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic nonsmall-cell lung cancer (NSCLC) receiving platinum chemotherapy. Lung Cancer 77:421-426. http://dx.doi.org/10.1016/j.lungcan.2012.04.005.
46. Garcia JV, Miller AD. 1991. Serine phosphorylation-independent downregulation of cell-surface CD4 by nef. Nature 350:508-511. http://dx.doi.org/10.1038/350508a0.
47. Rhee SS, Marsh JW. 1994. Human immunodeficiency virus type 1 Nefinduced down-modulation of CD4 is due to rapid internalization and degradation of surface CD4. J Virol 68:5156-5163.
48. Chen BK, Gandhi RT, Baltimore D. 1996. CD4 down-modulation during infection of human T cells with human immunodeficiency virus type 1 involves independent activities of vpu, env, and nef. J Virol 70:6044-6053.
49. Wildum S, Schindler M, Munch J, Kirchhoff F. 2006. Contribution of Vpu, Env, and Nef to CD4 down-modulation and resistance of human immunodeficiency virus type 1-infected T cells to superinfection. J Virol 80:8047-8059. http://dx.doi.org/10.1128/JVI.00252-06.
50. Stevenson M, Meier C, Mann AM, Chapman N, Wasiak A. 1988. Envelope glycoprotein of HIV induces interference and cytolysis resistance in CD4+ cells: mechanism for persistence in AIDS. Cell 53:483-496. http://dx.doi.org/10.1016/0092-8674(88)90168-7.
51. Geleziunas R, Bour S, Wainberg MA. 1994. Cell surface downmodulation of CD4 after infection by HIV-1. FASEB J 8:593-600.
52. Willey RL, Maldarelli F, Martin MA, Strebel K. 1992. Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4. J Virol 66:7193-7200.
53. Aiken C, Konner J, Landau NR, Lenburg ME, Trono D. 1994. Nef induces CD4 endocytosis: requirement for a critical dileucine motif in the membrane-proximal CD4 cytoplasmic domain. Cell 76:853-864. http://dx.doi.org/10.1016/0092-8674(94)90360-3.
54. Münch J, Rajan D, Schindler M, Specht A, Rucker E, Novembre FJ, Nerrienet E, Muller-Trutwin MC, Peeters M, Hahn BH, Kirchhoff F. 2007. Nef-mediated enhancement of virion infectivity and stimulation of viral replication are fundamental properties of primate lentiviruses. J Virol 81:13852-13864. http://dx.doi.org/10.1128/JVI.00904-07.
55. Spina CA, Guatelli JC, Richman DD. 1995. Establishment of a stable, inducible form of human immunodeficiency virus type 1 DNA in quiescent CD4 lymphocytes in vitro. J Virol 69:2877-2988.
56. Mohammadi P, J di Iulio Munoz M, Martinez R, Bartha I, Cavassini M, Thorball C, Fellay J, Beerenwinkel N, Ciuffi A, Telenti A. 2014. Dynamics of HIV latency and reactivation in a primary CD4+ T cell model. PLoS Pathog 10:e1004156. http://dx.doi.org/10.1371/journal.ppat.1004156.
57. Wu Y, Marsh JW. 2001. Selective transcription and modulation of resting T cell activity by preintegrated HIV DNA. Science 293:1503-1506. http://dx.doi.org/10.1126/science.1061548.
58. Cullen BR, Malim MH. 1990. Regulation of HIV-1 gene expression. Nucleic Acids Mol Biol 4:176-184. http://dx.doi.org/10.1007/978-3-642-84150-7_11.
59. Kutsch O, Benveniste EN, Shaw GM, Levy DN. 2002. Direct and quantitative single-cell analysis of human immunodeficiency virus type 1 reactivation from latency. J Virol 76:8776-8786. http://dx.doi.org/10.1128/JVI.76.17.8776-8786.2002.
60. Pasternak AO, Jurriaans S, Bakker M, Prins JM, Berkhout B, Lukashov VV. 2009. Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcome. PLoS One 4:e8490. http://dx.doi.org/10.1371/journal.pone.0008490.
61. Eisele E, Siliciano RF. 2012. Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity 37:377-388. http://dx.doi.org/10.1016/j.immuni.2012.08.010.
62. Piguet V, Schwartz O, Le Gall S, Trono D. 1999. The downregulation of CD4 and MHC-I by primate lentiviruses: a paradigm for the modulation of cell surface receptors. Immunol Rev 168:51-63. http://dx.doi.org/10.1111/j.1600-065X.1999.tb01282.x.
63. Glushakova S, Munch J, Carl S, Greenough TC, Sullivan JL, Margolis L, Kirchhoff F. 2001. CD4 down-modulation by human immunodeficiency virus type 1 Nef correlates with the efficiency of viral replication and with CD4(+) T-cell depletion in human lymphoid tissue ex vivo. J Virol 75: 10113-10117. http://dx.doi.org/10.1128/JVI.75.21.10113-10117.2001.
64. Lassen KG, Bailey JR, Siliciano RF. 2004. Analysis of human immunodeficiency virus type 1 transcriptional elongation in resting CD4+ T cells in vivo. J Virol 78:9105-9114. http://dx.doi.org/10.1128/JVI.78.17.9105-9114.2004.
65. Wei DG, Chiang V, Fyne E, Balakrishnan M, Barnes T, Graupe M, Hesselgesser J, Irrinki A, Murry JP, Stepan G, Stray KM, Tsai A, Yu H, Spindler J, Kearney M, Spina CA, McMahon D, Lalezari J, Sloan D, Mellors J, Geleziunas R, Cihlar T. 2014. Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. PLoS Pathog 10:e1004071. http://dx.doi.org/10.1371/journal.ppat.1004071.
66. Cillo AR, Sobolewski MD, Bosch RJ, Fyne E, Piatak M, Jr, Coffin JM, Mellors JW. 2014. Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A 111:7078-7083. http://dx.doi.org/10.1073/pnas.1402873111.
67. Spina CA, Anderson J, Archin NM, Bosque A, Chan J, Famiglietti M, Greene WC, Kashuba A, Lewin SR, Margolis DM, Mau M, Ruelas D, Saleh S, Shirakawa K, Siliciano RF, Singhania A, Soto PC, Terry VH, Verdin E, Woelk C, Wooden S, Xing S, Planelles V. 2013. An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients. PLoS Pathog 9:e1003834. http://dx.doi.org/10.1371/journal.ppat.1003834.
68. Cameron PU, Saleh S, Sallmann G, Solomon A, Wightman F, Evans VA, Boucher G, Haddad EK, Sekaly RP, Harman AN, Anderson JL, Jones KL, Mak J, Cunningham AL, Jaworowski A, Lewin SR. 2010. Establishment of HIV-1 latency in resting CD4+ T cells depends on chemokine-induced changes in the actin cytoskeleton. Proc Natl Acad Sci U S A 107:16934-16939.
69. Saleh S, Solomon A, Wightman F, Xhilaga M, Cameron PU, Lewin SR. 2007. CCR7 ligands CCL19 and CCL21 increase permissiveness of resting memory CD4+ T cells to HIV-1 infection: a novel model of HIV-1 latency. Blood 110:4161-4164. http://dx.doi.org/10.1182/blood-2007-06-097907.
70. Chavez L, Calvanese V, Verdin E. 2015. HIV latency is established directly and early in both resting and activated primary CD4 T cells. PLoS Pathog 11:e1004955. http://dx.doi.org/10.1371/journal.ppat.1004955.
71. Vatakis DN, Bristol G, Wilkinson TA, Chow SA, Zack JA. 2007. Immediate activation fails to rescue efficient human immunodeficiency virus replication in quiescent CD4+T cells. J Virol 81:3574-3582. http://dx.doi.org/10.1128/JVI.02569-06.
72. Lucera MB, Tilton CA, Mao H, Dobrowolski C, Tabler CO, Haqqani AA, Karn J, Tilton JC. 2014. The histone deacetylase inhibitor vorinostat (SAHA) increases the susceptibility of uninfected CD4+T cells to HIV by increasing the kinetics and efficiency of postentry viral events. J Virol 88:10803-10812. http://dx.doi.org/10.1128/JVI.00320-14.
73. Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, Boucher G, Boulassel MR, Ghattas G, Brenchley JM, Schacker TW, Hill BJ, Douek DC, Routy JP, Haddad EK, Sekaly RP. 2009. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 15:893-900. http://dx.doi.org/10.1038/nm.1972.
74. Ostrowski MA, Chun T-W, Justement SJ, Motola I, Spinelli MA, Adelsberger J, Ehler LA, Mizell SB, Hallahan CW, Fauci AS. 1999. Both memory and CD45RA(+)/CD62L(+) naive CD4(+) T cells are infected in human immunodeficiency type 1-infected individuals. J Virol 73:6430-6435.
75. Dai J, Agosto LM, Baytop C, Yu JJ, Pace MJ, Liszewski MK, O'Doherty U. 2009. Human immunodeficiency virus integrates directly into naive resting CD4+ T cells but enters naive cells less efficiently than memory cells. J Virol 83:4528-4537. http://dx.doi.org/10.1128/JVI.01910-08.
76. Yukl SA, Sinclair E, Somsouk M, Hunt PW, Epling L, Killian M, Girling V, Li P, Havlir DV, Deeks SG, Wong JK, Hatano H. 2014. A comparison of methods for measuring rectal HIV levels suggests that HIVDNAresides in cells other than CD4+ T cells, including myeloid cells. AIDS 28:439-442. http://dx.doi.org/10.1097/QAD.0000000000000166.
77. Iyer SR, Yu D, Biancotto A, Margolis LB, Wu Y. 2009. Measurement of human immunodeficiency virus type 1 preintegration transcription by using Rev-dependent Rev-CEM cells reveals a sizable transcribing DNA population comparable to that from proviral templates. J Virol 83:8662-8673. http://dx.doi.org/10.1128/JVI.00874-09.
78. Merzouki A, Patel P, Cassol S, Ennaji M, Tailor P, Turcotte FR, O'Shaughnessy M, Arella M. 1995. HIV-1 gp120/160 expressing cells upregulate HIV-1 LTR directed gene expression in a cell line transfected with HIV-1 LTR-reporter gene constructs. Cell Mol Biol 41:445-452.
79. Imamichi H, Natarajan V, Adelsberger JW, Rehm CA, Lempicki RA, Das B, Hazen A, Imamichi T, Lane HC. 2014. Lifespan of effector memory CD4+T cells determined by replication-incompetent integrated HIV-1 provirus. AIDS 28:1091-1099. http://dx.doi.org/10.1097/QAD.0000000000000223.
80. Chun TW, Nickle DC, Justement JS, Large D, Semerjian A, Curlin ME, O'Shea MA, Hallahan CW, Daucher M, Ward DJ, Moir S, Mullins JI, Kovacs C, Fauci AS. 2005. HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J Clin Invest 115:3250-3255. http://dx.doi.org/10.1172/JCI26197.
81. Lambotte O, Chaix ML, Gubler B, Nasreddine N, Wallon C, Goujard C, Rouzioux C, Taoufik Y, Delfraissy JF. 2004. The lymphocyte HIV reservoir in patients on long-term HAART is a memory of virus evolution. AIDS 18:1147-1158. http://dx.doi.org/10.1097/00002030-200405210-00008.
82. Coiras M, Lopez-Huertas MR, Perez-Olmeda M, Alcami J. 2009. Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nat Rev Microbiol 7:798-812. http://dx.doi.org/10.1038/nrmicro2223.
83. Hellerstein M, Hanley MB, Cesar D, Siler S, Papageorgopoulos C, Wieder E, Schmidt D, Hoh R, Neese R, Macallan D, Deeks S, McCune JM. 1999. Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans. Nat Med 5(1):83-89. http://dx.doi.org/10.1038/4772.
84. Murray JM, Zaunders JJ, McBride KL, Xu Y, Bailey M, Suzuki K, Cooper DA, Emery S, Kelleher AD, Koelsch KK, Team PS. 2014. HIV DNA subspecies persist in both activated and resting memory CD4+ T cells during antiretroviral therapy. J Virol 88:3516-3526. http://dx.doi.org/10.1128/JVI.03331-13.
85. Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, Parker DC, Anderson EM, Kearney MF, Strain MC, Richman DD, Hudgens MG, Bosch RJ, Coffin JM, Eron JJ, Hazuda DJ, Margolis DM. 2012. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487:482-485. http://dx.doi.org/10.1038/nature11286.
86. Lassen KG, Ramyar KX, Bailey JR, Zhou Y, Siliciano RF. 2006. Nuclear retention of multiply spliced HIV-1 RNA in resting CD4+ T cells. PLoS Pathog 2:e68. http://dx.doi.org/10.1371/journal.ppat.0020068.
87. Archin NM, Bateson R, Tripathy M, Crooks AM, Yang KH, Dahl NP, Kearney MF, Anderson EM, Coffin JM, Strain MC, Richman DD, Robertson KR, Kashuba AD, Bosch RJ, Hazuda DJ, Kuruc JD, Eron JJ, Margolis DM. 2014. HIV-1 expression within resting CD4 T-cells following multiple doses of vorinostat. J Infect Dis 210:728-735. http://dx.doi.org/10.1093/infdis/jiu155.
88. Jones RB, O'Connor R, Mueller S, Foley M, Szeto GL, Karel D, Lichterfeld M, Kovacs C, Ostrowski MA, Trocha A, Irvine DJ, Walker BD. 2014. Histone deacetylase inhibitors impair the elimination of HIVinfected cells by cytotoxic T-lymphocytes. PLoS Pathog 10:e1004287. http://dx.doi.org/10.1371/journal.ppat.1004287.
89. Shan L, Deng K, Shroff NS, Durand CM, Rabi SA, Yang H-C, Zhang H, Margolick JB, Blankson JN, Siliciano RF. 2012. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 36:491-501. http://dx.doi.org/10.1016/j.immuni.2012.01.014.
90. Buckheit RW, III, Siliciano RF, Blankson JN. 2013. Primary CD8+ T cells from elite suppressors effectively eliminate non-productively HIV-1 infected resting and activated CD4+ T cells. Retrovirology 10:68. http://dx.doi.org/10.1186/1742-4690-10-68.
91. Migueles SA, Osborne CM, Royce C, Compton AA, Joshi RP, Weeks KA, Rood JE, Berkley AM, Sacha JB, Cogliano-Shutta NA, Lloyd M, Roby G, Kwan R, McLaughlin M, Stallings S, Rehm C, O'Shea MA, Mican J, Packard BZ, Komoriya A, Palmer S, Wiegand AP, Maldarelli F, Coffin JM, Mellors JW, Hallahan CW, Follman DA, Connors M. 2008. Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity 29:1009-1021. http://dx.doi.org/10.1016/j.immuni.2008.10.010.